Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

The study will start with a single dose ascending (SAD) phase. LMG324 will be administered on
Day 1 with no further treatment until implementation of standard of care (SoC) therapy. SoC
therapy is ranibizumab 0.5 mg administered per label. Dose groups will be implemented
sequentially to allow for safety review between the current and subsequent dose group. All
treatments will be open-label, including ranibizumab used as SoC therapy.

In the enrollment expansion phase, subjects randomized to LMG324 arm will receive a single
LMG324 IVT injection on Day 1 followed by sham (fake) IVT injections until implementation of
SoC therapy. After implementation, SoC therapy will be applied monthly with sham injections
applied at the interim planned visits. The enrollment expansion phase may start at a selected
dose level whilst the dose escalation phase is still ongoing.

Inclusion Criteria:

- Must give written informed consent, be able to make the required study visits and
follow instructions.

- Male and non-child bearing potential females.

- Untreated or previously treated choroidal neovascularization (CNV) lesion due to
age-related macular degeneration (AMD).

- Best corrected visual acuity (BCVA) of approximately 20/200 Snellen or better in the
non-study eye.

SAD population only:

- CNV lesion due to AMD - either treatment naïve or previously treated - that can be
expected to benefit from anti-VEGF therapy, in the study eye.

- At least 3 administrations of any IVT anti-VEGF therapeutic for the treatment of CNV
with the last injection administered ≥ 1 month prior to the planned administration of
the study drug, in previously treated eyes.

Enrollment expansion population only:

- Untreated and active CNV lesion due to AMD, in the study eye.

- BCVA between 73 - 23 letters, inclusive (approximate Snellen equivalent 20/40 -
20/320), in the study eye.

- Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

- Either eye: Active ocular infection or active intraocular inflammation.

- Study eye: Current vitreous hemorrhage or a history of rhegmatogenous retinal
detachment; uncontrolled glaucoma.

SAD population only:

- Any contraindications to IVT anti-VEGF therapeutic administration.

Enrollment expansion population only:

- Study Eye: Any approved or investigational treatment for exudative AMD other than
vitamin supplements; any macular or retinal disease other than exudative AMD; any
intraocular condition that could require medical or surgical intervention during the
study or limit the potential to gain visual acuity upon treatment with the
investigational product; ocular diseases that can compromise visual acuity.

- Other protocol-specified exclusion criteria may apply.